X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes. MLR-1023, a lyn kinase activator, which has shown exceptional clinical safety and tolerability in Phase 2a and Phase 2b Type 2 diabetes.
Lead Product(s): Tolimidone
Therapeutic Area: Endocrinology Product Name: MLR-102
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Adhera Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 24, 2021
Details:
Melior has uncovered a previously unreported therapeutic potential of MLR-1019 in PD. As such it represents a new class of PD therapeutic which may be the only drug candidate to address both movement and non-movement aspects of PD.
Lead Product(s): Armesocarb
Therapeutic Area: Neurology Product Name: MLR-1019
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adhera Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2021
Details:
Under the terms of the intended acquisition, Adhera will continue clinical development of MLR-1019 (Armesocarb ). Melior Pharmaceuticals will receive Adhera stock plus royalties.
Lead Product(s): Armesocarb
Therapeutic Area: Neurology Product Name: MLR-1019
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adhera Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 07, 2021
Details:
The planned Phase 2 study is intended to recruit 236 subjects who were recently diagnosed with COVID-19, have early symptoms, but are not hospitalized. Tolimidone will be taken as an orally administered pill once a day.
Lead Product(s): Tolimidone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
The Phase 2 clinical trial is intended to test tolimidone in subjects who were recently diagnosed with COVID19, but are not hospitalized. Tolimidone is expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications.
Lead Product(s): Tolimidone
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Commonwealth of Pennsylvania’s COVID-19 Vaccines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
